Profiles of HBcrAg and pgRNA in Pregnant Women With Chronic HBV Under Different Disease Phases and Antiviral Prophylaxis

作者全名：Wang, Chun-Rui; Liu, Xiao-qin; Shen, Wei; Zhong, Guo-Chao; Li, Hu; Tang, Qiao; Liu, Yu-Xing; Hu, Peng

作者地址：[Wang, Chun-Rui; Liu, Xiao-qin; Shen, Wei; Li, Hu; Tang, Qiao; Liu, Yu-Xing; Hu, Peng] Chongqing Med Univ, Inst Viral Hepatitis, Dept Infect Dis,Chinese Minist Educ, Affiliated Hosp 2,Key Lab Mol Biol Infect Dis, 76 Linjiang Rd,Yuzhong Dist, Chongqing 400010, Peoples R China; [Zhong, Guo-Chao] Chongqing Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 2, Yuzhong Dist, Chongqing, Peoples R China

通信作者：Hu, P (通讯作者)，Chongqing Med Univ, Inst Viral Hepatitis, Dept Infect Dis,Chinese Minist Educ, Affiliated Hosp 2,Key Lab Mol Biol Infect Dis, 76 Linjiang Rd,Yuzhong Dist, Chongqing 400010, Peoples R China.

来源：OPEN FORUM INFECTIOUS DISEASES

ESI学科分类：IMMUNOLOGY

WOS号：WOS:001224188900003

JCR分区：Q2

影响因子：3.8

年份：2024

卷号：11

期号：5

开始页：　

结束页：　

文献类型：Article

关键词：different stages; HBcrAg; HBV in pregnancy; mother-to-child transmission; pgRNA

摘要：Background Pregnant women with chronic hepatitis B (CHB) exhibit unique clinical features in terms of postpartum immune system reconstitution and recovery from pregnancy-related changes. However, current studies focus primarily on the outcomes of maternal-infant transmission and postpartum hepatitis flares. We aimed to evaluate the profiles of hepatitis B core-related antigen (HBcrAg) and pregenomic RNA (pgRNA) in pregnant women with CHB. Methods This retrospective analysis included treatment-na & iuml;ve pregnant women with CHB who were followed up regularly in an outpatient clinic from 2014 to 2021. Baseline HBcrAg and pgRNA levels were compared in patients with different disease phases. Changes in these parameters were examined in a subset of patients receiving antiviral prophylaxis. HBcrAg and pgRNA levels were measured before treatment, at 32 weeks of gestation, and postpartum. Results The final analysis included a total of 121 patients, 100 of whom were hepatitis B e antigen (HBeAg)-positive (96 and 4 in the immune-tolerant and -indeterminate phases, respectively) and 21 of whom were HBeAg-negative (6 and 15 in the immune-active and -inactive carrier phases, respectively). The HBeAg-negative group vs the HBeAg-positive group had lower levels of baseline HBcrAg (median [interquartile range {IQR}], 3.7 [3.0-5.9] vs 8.6 [8.4-8.7] log(10) U/mL; P < .01) and pgRNA (median [IQR], 0.0 [0.0-2.5] vs 7.8 [7.6-8.1] log(10) copies/mL; P < .01). The serum levels of HBcrAg and pgRNA were highest in immune-tolerant carriers and lowest in immune-inactive carriers. In HBeAg-positive patients, the correlation coefficients of HBcrAg and pgRNA with hepatitis B virus (HBV) DNA were 0.40 and 0.43, respectively; in HBeAg-negative patients, they were 0.53 and 0.51, respectively (all P < .05). The correlation coefficients with hepatitis B surface antigen (HBsAg) were 0.55 and 0.52 (P < .05) in HBeAg-positive patients, respectively, while in HBeAg-negative patients they were 0.42 and 0.37, respectively (P > .05). Among 96 patients receiving antiviral prophylaxis, we detected a rapid decrease in HBV DNA to an undetectable level during treatment but relatively stable levels of pgRNA and HBcrAg. Conclusions HBcrAg and pgRNA levels are lower in HBeAg-negative patients than in HBeAg-positive patients. These 2 markers are significantly associated with HBV DNA irrespective of HBeAg status, while they are significantly associated with HBsAg only in HBeAg-positive patients.

基金机构：National Science and Technology Major Project of China [2017ZX10202203008, 2017ZX10202203007]; National Natural Science Foundation of China [81772171, 82203391]; Chongqing Talents Project [cstc2021ycjh-bgzxm0150]; Remarkable Innovation-Clinical Research Project; Second Affiliated Hospital of Chongqing Medical University

基金资助正文：This work was supported in part by grants from the National Science and Technology Major Project of China (2017ZX10202203008, 2017ZX10202203007), the National Natural Science Foundation of China (81772171, 82203391), the Chongqing Talents Project (cstc2021ycjh-bgzxm0150), Remarkable Innovation-Clinical Research Project, and the Second Affiliated Hospital of Chongqing Medical University.